PRESS RELEASES<< Back
Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 3891009. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Brincidofovir (BCV, CMX001) uses Chimerix's proprietary lipid conjugate technology. For further information, please visit Chimerix's website, www.chimerix.com.
Stern Investor Relations
Source: Chimerix, Inc.